These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32905529)

  • 1. Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.
    Goto T; Kashiwagi E; Jiang G; Nagata Y; Teramoto Y; Baras AS; Yamashita S; Ito A; Arai Y; Miyamoto H
    Am J Cancer Res; 2020; 10(8):2523-2534. PubMed ID: 32905529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
    Kashiwagi E; Inoue S; Mizushima T; Chen J; Ide H; Kawahara T; Reis LO; Baras AS; Netto GJ; Miyamoto H
    Br J Cancer; 2018 Jan; 118(2):213-223. PubMed ID: 29123257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
    Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer.
    Teramoto Y; Jiang G; Goto T; Mizushima T; Nagata Y; Netto GJ; Miyamoto H
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells.
    Ide H; Mizushima T; Jiang G; Goto T; Nagata Y; Teramoto Y; Inoue S; Li Y; Kashiwagi E; Baras AS; Netto GJ; Kawahara T; Miyamoto H
    Endocr Relat Cancer; 2020 Apr; 27(4):231-244. PubMed ID: 32031965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer.
    Jiang G; Teramoto Y; Goto T; Mizushima T; Inoue S; Ide H; Nagata Y; Kashiwagi E; Baras AS; Netto GJ; Yang Z; Miyamoto H
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33652650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.
    Ide H; Inoue S; Miyamoto H
    PLoS One; 2017; 12(3):e0174746. PubMed ID: 28362839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
    Altundag O; Altundag K; Gunduz M
    Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development.
    Hsu I; Chuang KL; Slavin S; Da J; Lim WX; Pang ST; O'Brien JH; Yeh S
    Carcinogenesis; 2014 Mar; 35(3):651-61. PubMed ID: 24148819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
    Tee MK; Rogatsky I; Tzagarakis-Foster C; Cvoro A; An J; Christy RJ; Yamamoto KR; Leitman DC
    Mol Biol Cell; 2004 Mar; 15(3):1262-72. PubMed ID: 14699072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
    Elahi Najafi MA; Yasui M; Teramoto Y; Tatenuma T; Jiang G; Miyamoto H
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.
    Kawahara T; Ide H; Kashiwagi E; Patterson JD; Inoue S; Shareef HK; Aljarah AK; Zheng Y; Baras AS; Miyamoto H
    Am J Cancer Res; 2015; 5(10):2959-68. PubMed ID: 26693052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
    Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P
    Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal regulation of estrogen receptor alpha and beta gene expression in human granulosa-luteal cells in vitro.
    Chiang CH; Cheng KW; Igarashi S; Nathwani PS; Leung PC
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3828-39. PubMed ID: 11061546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
    Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
    Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
    Power KA; Thompson LU
    Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity.
    Belcher SM; Burton CC; Cookman CJ; Kirby M; Miranda GL; Saeed FO; Wray KE
    BMC Pharmacol Toxicol; 2017 Sep; 18(1):63. PubMed ID: 28877739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.